Literature DB >> 31381161

Surgical treatment for pelvic Ewing sarcoma: What is a safe and functional acetabular reconstruction when combined with modern multidisciplinary treatments?

Tomohiro Fujiwara1,2, Johnathan R Lex1, Jonathan D Stevenson1, Yusuke Tsuda1, Rhys Clark1, Michael C Parry1, Robert J Grimer1, Lee M Jeys1.   

Abstract

PURPOSE: The purpose of this study was to clarify which local treatment is oncologically and functionally effective in pelvic Ewing sarcoma (ES).
METHODS: A consecutive series of patients who underwent pelvic resections and acetabular reconstructions after chemotherapy between 1986 and 2016 at a supra-regional center were evaluated.
RESULTS: The cohort consisted of 35 patients. The 5-year overall survival (OS) and local recurrence-free survival (LRFS) was 61% and 72%, respectively. Preoperative radiotherapy (RT) and surgery provided an excellent/good histological response in 92% and achieved significantly better OS (5 years, 64%) and LRFS (5 years, 100%) than surgery alone or surgery with postoperative RT. The Musculoskeletal Tumor Society functional scores were significantly better in patients with hip transposition than those with structural reconstructions (74% vs 57%; P = .031) using custom-made prostheses, irradiated autografts, and ice-cream cone prostheses. These scores were significantly lower if patients had deep infection (P = .035), which was the most common complication (28%) in structural reconstructions but did not occur in hip transposition even when performed after preoperative RT.
CONCLUSION: Acetabular reconstruction with hip transposition resulted in no deep infection and superior function in patients with pelvic ES even when combined with preoperative RT, which improved tumor necrosis and rate of local control and survival.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  Ewing sarcoma; pelvis; radiotherapy; reconstruction; surgery

Mesh:

Year:  2019        PMID: 31381161     DOI: 10.1002/jso.25660

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  7 in total

1.  CORR Insights®: Does Adding Femoral Lengthening at the Time of Rotation Hip Transposition After Periacetabular Tumor Resection Allow for Restoration of Limb Length and Function? Interim Results of a Modified Hip Transposition Procedure.

Authors:  Ajay Puri
Journal:  Clin Orthop Relat Res       Date:  2021-07-01       Impact factor: 4.755

Review 2.  Musculoskeletal oncology reconstructions in India - Changes in this millennium!

Authors:  Ajay Puri
Journal:  J Clin Orthop Trauma       Date:  2021-06-09

3.  Reconstruction with customized, 3D-printed prosthesis after resection of periacetabular Ewing's sarcoma in children using "triradiate cartilage-based" surgical strategy:a technical note.

Authors:  Dongze Zhu; Jun Fu; Ling Wang; Zheng Guo; Zhen Wang; Hongbin Fan
Journal:  J Orthop Translat       Date:  2021-03-26       Impact factor: 5.191

4.  Extra-articular resection of the hip joint for pelvic sarcomas: Are there any oncological and functional risks compared with intra-articular resection?

Authors:  Tomohiro Fujiwara; Yusuke Tsuda; Jonathan Stevenson; Michael Parry; Lee Jeys
Journal:  J Bone Oncol       Date:  2021-11-01       Impact factor: 4.072

5.  Clinical application of 3D-printed patient-specific guide plate combined with computer navigation in acetabular reconstruction following resection of periacetabular tumors.

Authors:  Jingyi Dang; Jun Fu; Dong Liu; Zhao Zhang; Zhenzhou Mi; Debin Cheng; Xincheng Liu; Yushen Zhang; Dongze Zhu; Lei Wang; Yubo Shi; Hongbin Fan
Journal:  Ann Transl Med       Date:  2022-01

6.  The Need for Multidisciplinarity in Modern Medicine: An Insight into Orthopaedic Infections.

Authors:  Andrea Sambri; Michele Fiore; Sara Tedeschi; Massimiliano De Paolis
Journal:  Microorganisms       Date:  2022-03-31

7.  Comparison of local control and survival outcomes between surgical and non-surgical local therapy on pelvic Ewing's sarcoma patients: a meta-analysis.

Authors:  Xianbiao Xie; Ziliang Zeng; Hao Yao; Qinglin Jin; Yiying Bian; Dongming Lv; Jian Tu; Bo Wang; Lili Wen; Jingnan Shen
Journal:  Transl Cancer Res       Date:  2020-10       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.